Phosphodiesterase Type 5 (PDE5) Inhibitors & Exposure in Pregnancy

Basic Details
Last Updated
Monday, March 18, 2019
Health Outcome(s)
exposure in pregnancy
Drug Use
Regulatory Determination / Use

Use of PDE5 inhibitors was assessed among reproductive age women, including among pregnant women, to investigate a concern arising from an international clinical trial.  FDA decided that no action is necessary at this time, based on available information.